Develops and produces in vitro diagnostic solutions. Offers systems for diagnosing infectious diseases. Now — the numbers.
This is an established company with proven profits.
No real growth (5% a year).
If every debt were paid off today, $125.7M would still be left in the vault — a solid cushion for hard times.
The market pays 22.7× for every dollar of annual profit — around what a business like this usually costs.
No analyst target is on record for this company.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
An investor who bought at the very peak is down 92% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $660.8M in the vault; even if every debt were paid off, $125.7M would remain.
It pays out $0.11 per share each year — regular cash for whoever holds the stock.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.